Biologic Therapeutic Discovery, Amgen Research, South San Francisco, CA, USA.
Biologic Therapeutic Discovery, Amgen Research, Thousand Oaks, CA, USA.
MAbs. 2023 Jan-Dec;15(1):2207232. doi: 10.1080/19420862.2023.2207232.
We are entering an era in which therapeutic proteins are assembled using building block-like strategies, with no standardized schema to discuss these formats. Existing nomenclatures, like AbML, sacrifice human readability for precision. Therefore, considering even a dozen such formats, in combination with hundreds of possible targets, can create confusion and increase the complexity of drug discovery. To address this challenge, we introduce Verified Taxonomy for Antibodies (VERITAS). This classification and nomenclature scheme is extensible to multispecific therapeutic formats and beyond. VERITAS names are easy to understand while drawing direct connections to the structure of a given format, with or without specific target information, making these names useful to adopt in scientific discourse and as inputs to machine learning algorithms for drug development.
我们正步入一个使用积木式策略来组装治疗性蛋白的时代，但却没有标准化的方案来讨论这些形式。现有的命名法，如 AbML，为了精确而牺牲了人类的可读性。因此，即使考虑十几个这样的格式，再加上数百个可能的靶点，也可能会造成混淆并增加药物发现的复杂性。为了解决这个挑战，我们引入了抗体验证分类法（VERITAS）。这个分类和命名方案可扩展到多特异性治疗性格式及其他形式。VERITAS 名称易于理解，同时与给定格式的结构直接关联，无论是否有特定的目标信息，这使得这些名称在科学论述中很有用，并且可以作为药物开发的机器学习算法的输入。
